Prebiotics, synbiotics and inflammatory bowel disease
- PMID: 18383235
- DOI: 10.1002/mnfr.200700139
Prebiotics, synbiotics and inflammatory bowel disease
Abstract
The normal colonic microflora is intimately involved in the aetiology of inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD). These conditions are often refractile to conventional treatments involving the employment of anti-inflammatory and immunosuppressant drugs, and this has led to a search for alternative therapies based on the use of probiotics, prebiotics and synbiotics. The majority of investigations in this area have been done with probiotics, and while there is increasing interest in the abilities of prebiotics and synbiotics to control the symptoms of IBD, very few randomised controlled trials have been reported. Although the results have been variable, human and animal studies have demonstrated that in many circumstances, these functional foods can alter the composition of the colonic microbiota, reduce inflammatory processes in the gut mucosa, and have the potential to induce disease remission. More work is needed to understand the effects of prebiotics and synbiotics on microbial communities in the gut, and their interactions with the host's immune system.
Similar articles
-
Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?Mol Nutr Food Res. 2008 Aug;52(8):906-12. doi: 10.1002/mnfr.200700147. Mol Nutr Food Res. 2008. PMID: 18384087 Review.
-
Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials.Proc Nutr Soc. 2007 Aug;66(3):307-15. doi: 10.1017/S0029665107005563. Proc Nutr Soc. 2007. PMID: 17637082 Review.
-
Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease.Expert Opin Ther Targets. 2008 Mar;12(3):301-12. doi: 10.1517/14728222.12.3.301. Expert Opin Ther Targets. 2008. PMID: 18269340 Review.
-
Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics.Int J Food Microbiol. 2007 Apr 1;115(1):1-11. doi: 10.1016/j.ijfoodmicro.2006.10.006. Epub 2006 Nov 28. Int J Food Microbiol. 2007. PMID: 17137666 Review.
-
Inflammatory bowel disease, gut bacteria and probiotic therapy.Int J Med Microbiol. 2010 Jan;300(1):25-33. doi: 10.1016/j.ijmm.2009.08.004. Epub 2009 Oct 2. Int J Med Microbiol. 2010. PMID: 19800289 Review.
Cited by
-
Nutraceuticals and Diet Supplements in Crohn's Disease: A General Overview of the Most Promising Approaches in the Clinic.Foods. 2022 Apr 4;11(7):1044. doi: 10.3390/foods11071044. Foods. 2022. PMID: 35407131 Free PMC article. Review.
-
Microbial biofilms and gastrointestinal diseases.Pathog Dis. 2013 Feb;67(1):25-38. doi: 10.1111/2049-632X.12020. Epub 2013 Jan 29. Pathog Dis. 2013. PMID: 23620117 Free PMC article. Review.
-
Changes of intestinal microbiota and microbiota-based treatments in IBD.Arch Microbiol. 2022 Jul 1;204(7):442. doi: 10.1007/s00203-022-03069-4. Arch Microbiol. 2022. PMID: 35776212 Review.
-
Anti-inflammatory effects of newly synthesized α-galacto-oligosaccharides on dextran sulfate sodium-induced colitis in C57BL/6J mice.Food Res Int. 2018 Jul;109:350-357. doi: 10.1016/j.foodres.2018.04.054. Epub 2018 Apr 24. Food Res Int. 2018. PMID: 29803460 Free PMC article.
-
The Protective Effects of Ginseng Polysaccharides and Their Effective Subfraction against Dextran Sodium Sulfate-Induced Colitis.Foods. 2022 Mar 21;11(6):890. doi: 10.3390/foods11060890. Foods. 2022. PMID: 35327312 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
